ProShare Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $118M | Sell |
152,397
-31,889
| -17% | -$24.4M | 0.17% | 117 |
|
|
2025
Q4 | $142M | Buy |
184,286
+49,132
| +36% | +$33.4M | 0.25% | 117 |
|
|
2025
Q3 | $76M | Sell |
135,154
-34,189
| -20% | -$19.3M | 0.16% | 135 |
|
|
2025
Q2 | $88.9M | Buy |
169,343
+6,051
| +4% | +$3.38M | 0.18% | 133 |
|
|
2025
Q1 | $104M | Buy |
163,292
+17,157
| +12% | +$11.8M | 0.23% | 120 |
|
|
2024
Q4 | $104M | Buy |
146,135
+26,018
| +22% | +$21.8M | 0.24% | 113 |
|
|
2024
Q3 | $126M | Buy |
120,117
+6,906
| +6% | +$7.69M | 0.31% | 100 |
|
|
2024
Q2 | $119M | Sell |
113,211
-11,992
| -10% | -$11.6M | 0.32% | 102 |
|
|
2024
Q1 | $121M | Buy |
125,203
+21,604
| +21% | +$20.5M | 0.32% | 101 |
|
|
2023
Q4 | $91M | Sell |
103,599
-18,022
| -15% | -$14.8M | 0.28% | 104 |
|
|
2023
Q3 | $100M | Buy |
121,621
+12,984
| +12% | +$10.2M | 0.31% | 102 |
|
|
2023
Q2 | $78.1M | Sell |
108,637
-5,831
| -5% | -$4.5M | 0.23% | 104 |
|
|
2023
Q1 | $94.1M | Buy |
114,468
+9,788
| +9% | +$7.38M | 0.29% | 98 |
|
|
2022
Q4 | $75.5M | Sell |
104,680
-14,924
| -12% | -$11M | 0.27% | 98 |
|
|
2022
Q3 | $82.4M | Sell |
119,604
-23,334
| -16% | -$14.7M | 0.32% | 93 |
|
|
2022
Q2 | $84.5M | Sell |
142,938
-64,197
| -31% | -$41.7M | 0.28% | 101 |
|
|
2022
Q1 | $145M | Sell |
207,135
-8,932
| -4% | -$5.65M | 0.31% | 92 |
|
|
2021
Q4 | $136M | Buy |
216,067
+63,874
| +42% | +$39.3M | 0.27% | 107 |
|
|
2021
Q3 | $92.1M | Buy |
152,193
+16,450
| +12% | +$10.2M | 0.26% | 110 |
|
|
2021
Q2 | $75.8M | Sell |
135,743
-4,301
| -3% | -$2.18M | 0.22% | 116 |
|
|
2021
Q1 | $66.3M | Buy |
140,044
+19,031
| +16% | +$9.27M | 0.21% | 124 |
|
|
2020
Q4 | $58.5M | Buy |
121,013
+16,493
| +16% | +$8.9M | 0.22% | 119 |
|
|
2020
Q3 | $58.5M | Buy |
104,520
+18,638
| +22% | +$11.3M | 0.27% | 103 |
|
|
2020
Q2 | $53.6M | Buy |
85,882
+11,959
| +16% | +$6.79M | 0.29% | 97 |
|
|
2020
Q1 | $36.1M | Sell |
73,923
-30,717
| -29% | -$12.7M | 0.26% | 99 |
|
|
2019
Q4 | $39.3M | Sell |
104,640
-442
| -0.4% | -$149K | 0.18% | 112 |
|
|
2019
Q3 | $29.1M | Buy |
105,082
+2,893
| +3% | +$856K | 0.16% | 113 |
|
|
2019
Q2 | $32M | Sell |
102,189
-895
| -0.9% | -$298K | 0.19% | 110 |
|
|
2019
Q1 | $42.3M | Sell |
103,084
-2,169
| -2% | -$893K | 0.25% | 104 |
|
|
2018
Q4 | $39.3M | Buy |
105,253
+13,338
| +15% | +$4.88M | 0.28% | 98 |
|
|
2018
Q3 | $37.1M | Sell |
91,915
-17,851
| -16% | -$6.79M | 0.25% | 96 |
|
|
2018
Q2 | $37.9M | Sell |
109,766
-7,194
| -6% | -$2.25M | 0.25% | 101 |
|
|
2018
Q1 | $40.3M | Buy |
116,960
+130
| +0.1% | +$45.2K | 0.26% | 103 |
|
|
2017
Q4 | $43.9M | Buy |
116,830
+17,043
| +17% | +$6.9M | 0.3% | 91 |
|
|
2017
Q3 | $44.6M | Buy |
99,787
+10,478
| +12% | +$4.99M | 0.41% | 74 |
|
|
2017
Q2 | $43.9M | Buy |
89,309
+3,025
| +4% | +$1.32M | 0.44% | 71 |
|
|
2017
Q1 | $33.4M | Sell |
86,284
-12,964
| -13% | -$4.81M | 0.35% | 76 |
|
|
2016
Q4 | $36.4M | Buy |
99,248
+7,307
| +8% | +$2.78M | 0.4% | 73 |
|
|
2016
Q3 | $37M | Sell |
91,941
-24,704
| -21% | -$9.91M | 0.52% | 68 |
|
|
2016
Q2 | $40.7M | Buy |
116,645
+1,390
| +1% | +$535K | 0.52% | 64 |
|
|
2016
Q1 | $41.5M | Sell |
115,255
-14,503
| -11% | -$5.98M | 0.57% | 30 |
|
|
2015
Q4 | $70.4M | Buy |
129,758
+7,064
| +6% | +$3.83M | 0.85% | 19 |
|
|
2015
Q3 | $57.1M | Buy |
122,694
+5,534
| +5% | +$2.97M | 0.8% | 19 |
|
|
2015
Q2 | $59.8M | Sell |
117,160
-11,278
| -9% | -$5.5M | 0.83% | 18 |
|
|
2015
Q1 | $58M | Buy |
128,438
+15,623
| +14% | +$6.62M | 0.68% | 22 |
|
|
2014
Q4 | $46.3M | Buy |
112,815
+27,202
| +32% | +$10.7M | 0.54% | 31 |
|
|
2014
Q3 | $30.9M | Buy |
85,613
+16,265
| +23% | +$5.45M | 0.41% | 36 |
|
|
2014
Q2 | $19.6M | Sell |
69,348
-13,827
| -17% | -$4.1M | 0.25% | 65 |
|
|
2014
Q1 | $25M | Buy |
83,175
+6,351
| +8% | +$1.96M | 0.31% | 53 |
|
|
2013
Q4 | $21.1M | Buy |
76,824
+24,894
| +48% | +$7.16M | 0.32% | 59 |
|
|
2013
Q3 | $16.2M | Buy |
51,930
+4,648
| +10% | +$1.22M | 0.39% | 36 |
|
|
2013
Q2 | $10.6M | Buy |
+47,282
| New | +$11M | 0.21% | 86 |
|
Other funds holding REGN
VCM
N
ProShare Advisors's REGN Position: Q1 2026 in Review
ProShare Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 17% in Q1 2026, selling an estimated $24.4M and leaving 152,397 shares worth $118M. The position accounts for 0.17% of the portfolio, ranked #117.
ProShare Advisors first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $145M in Q1 2022. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- ProShare Advisors held 152,397 shares of Regeneron Pharmaceuticals worth $118M as of Q1 2026.
- ProShare Advisors sold 31,889 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $24.4M.
- Regeneron Pharmaceuticals made up 0.17% of ProShare Advisors's portfolio in Q1 2026, its #117 holding.
- ProShare Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- ProShare Advisors's Regeneron Pharmaceuticals position peaked at $145M in Q1 2022.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.